size-exclusion chromatography is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-02-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
定量分析的主流方法是反相高效液相色谱联用紫外或质谱检测，利用肽在疏水固定相上的保留行为确定纯度与含量。对于生物基质中的浓度测定，常采用液相色谱串联质谱，并配合固相萃取或蛋白沉淀进行样品前处理。免疫分析法也可使用，但可能受到结构相关肽的交叉反应干扰。
纯度评估通常综合反相色谱、体积排阻色谱与质谱三方面信息：前者反映疏水性杂质，后者反映聚集体，质谱则确认分子量与主要降解产物。有关降解途径的完整图谱——例如脱酰胺、氧化与水解各占多大比例——在不同储存条件下仍有差异，属于需要逐案验证的问题。
质量控制环节关注外观、含量、纯度、有关物质、水分与微生物限度等项目。检测结果需要有对照品和系统适用性数据支持，单次测定不足以判定批次的稳定性。实验室之间方法转移时，色谱柱品牌与梯度差异常导致保留时间漂移，因此方法验证十分必要。
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
| Property | Value | Notes |
|---|---|---|
| 储存温度 | 2 至 8 摄氏度 | 固体粉末，避光密封 |
| 外观 | 白色至类白色冻干粉 | 溶解后为澄清至微乳光 |
| 溶解性 | 易溶于水性缓冲液 | 避免剧烈振荡 |
| 常规纯度方法 | 反相高效液相色谱 | 紫外或质谱检测 |
| 定量方法 | 液相色谱串联质谱 | 配合固相萃取前处理 |
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
The energy expenditure of another ATP in this step is justified in 2 ways: The glycolytic process (up to this step) becomes irreversible, and the energy supplied destabilizes the molecule. Because the reaction catalyzed by phosphofructokinase 1 (PFK-1) is coupled to the hydrolysis of ATP (an energetically favorable step) it is, in essence, irreversible, and a distinct pathway must be used to do the reverse conversion during gluconeogenesis. This makes the reaction a key regulatory point (see below). Furthermore, the second phosphorylation event is necessary to allow the formation of two charged groups (rather than only one) in the subsequent step of glycolysis, ensuring the prevention of free diffusion of substrates out of the cell. The same reaction can also be catalyzed by pyrophosphate-dependent phosphofructokinase (PFP or PPi-PFK), which is found in most plants, some bacteria, archea, and protists, but not in animals. This enzyme uses pyrophosphate (PPi) as a phosphate donor instead of ATP. It is a reversible reaction, increasing the flexibility of glycolytic metabolism. A rarer ADP-dependent PFK enzyme variant has been identified in archaean species. Cofactors: Mg2+
The energy required to transform B, C, N, Si, and P from nonmetallic to metallic states has been estimated as 30, 100, 240, 33, and 50 kJ/mol, respectively. This indicates the proximity of boron to the metal-nonmetal borderline. Most of the chemistry of boron is nonmetallic in nature. Unlike its heavier congeners, it is not known to form a simple B3+ or hydrated [B(H2O)4]3+ cation. The small size of the boron atom enables the preparation of many interstitial alloy-type borides. Analogies between boron and transition metals have been noted in the formation of complexes, and adducts (for example, BH3 + CO →BH3CO and, similarly, Fe(CO)4 + CO →Fe(CO)5), as well as in the geometric and electronic structures of cluster species such as [B6H6]2− and [Ru6(CO)18]2−. The aqueous chemistry of boron is characterised by the formation of many different polyborate anions. Given its high charge-to-size ratio, boron bonds covalently in nearly all of its compounds; the exceptions are the borides as these include, depending on their composition, covalent, ionic, and metallic bonding components. Simple binary compounds, such as boron trichloride are Lewis acids as the formation of three covalent bonds leaves a hole in the octet which can be filled by an electron-pair donated by a Lewis base. Boron has a strong affinity for oxygen and a duly extensive borate chemistry. The oxide B2O3 is polymeric in structure, weakly acidic, and a glass former. Organometallic compounds of boron have been known since the 19th century (see organoboron chemistry).
== Early years == Of German descent, Christopher Richard Stein was born on 4 January 1947 in Churchill, Oxfordshire, to Eric Stein (1908–1965) and Dorothy Gertrude née Jackson (1909–1999). He was born and brought up on a farm. Stein was educated at Wells Court, a preparatory school just outside Tewkesbury, then Wells House, the Court's bigger sister-school at Malvern Wells, and then Uppingham School. He took A-levels in English, history and geography, but failed all of them. He moved to a cram school in Brighton, gaining E grades in English and history. Stein partially completed a hotel management traineeship with British Transport Hotels at its Great Western Royal Hotel in Paddington. He worked there as a chef for six months. Distraught by his father's suicide, at age 19 he went to Australia, where he worked as a labourer in an abattoir and as a clerk in a naval dockyard. To "take some time out" he travelled to New Zealand, where he picked asparagus, and Mexico. His 21st birthday was spent in Kaikōura, New Zealand, where he ate a rock lobster and slept under a bridge. Being on his own, he read widely, reflected on his attitude to education, and applied successfully to New College, Oxford, where he earned an English degree in 1971. Shortly after that, he moved to Padstow.
Sources: en.wikipedia.org
Bremelanotide was first developed by Palatin Technologies, then out-licensed to AMAG Pharmaceuticals Inc. after its approval by the FDA on 21 June 2019. Marked as VyleesiTM, it was primarily designed for both men and women in the form of an intranasal formulation, particularly for treating male erectile dysfunction. However, the research was discontinued and focused on targeting female HSDD in a subcutaneous injection to increase bioavailability. Bremelanotide is usually injected a minimum of 45 minutes before sexual activity. Despite having identical prescription criteria as that of flibanserin, bremelanotide is not recommended for pregnant patients. No trial was tested on pregnant patients. Therefore, patients at childbearing ages are recommended to use contraception continuously during treatment and should discontinue once they become pregnant.
=== Mongolian === A popular example of the longest suffixed word in Mongolian is "Цахилгаанжуулалтыхантайгаа" (tsakhilgaanjuulaltykhantaigaa) which is 26 letters long. Here is a table showing, with translations, which suffixes are added.
==== Feed additives ==== Enzymes are often added to animal feed to improve the health and growth of farmed animals, particularly chickens and pigs. The feed is typically treated with high pressure steam to kill bacteria such as Salmonella. Therefore the added enzymes (e.g. phytase and xylanase) must be able to withstand this thermal challenge without being irreversibly inactivated.
Sources: en.wikipedia.org
建议在低温、避光、干燥环境中密封保存，常见条件为 2 至 8 摄氏度，长期存放可置于更低温度。应避免反复冻融，并尽量减少容器开启次数。
溶解后的稳定时间通常短于固体形态，受浓度、缓冲液和容器材质影响。冷藏条件下一般只能维持较短时间，具体期限应通过实际稳定性实验确认。
反相高效液相色谱用于纯度与含量测定，液相色谱串联质谱用于生物基质中的定量，体积排阻色谱用于检测聚集体。多种方法结合才能较完整地表征样品。
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.